S-8

As filed with the Securities and Exchange Commission on March 13, 2025

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

REGENXBIO Inc.

(Exact name of registrant as specified in its charter)

Delaware	47-1851754
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
9804 Medical Center Drive Rockville, Maryland 20850
(Address of Principal Executive Offices and Zip Code)

2015 Equity Incentive Plan

(Full title of the plans)

Mitchell Chan

Chief Financial Officer

REGENXBIO Inc.

9804 Medical Center Drive

Rockville, Maryland 20850

(Name and address of agent for service)

(240) 552-8181

(Telephone number, including area code, of agent for service)

Copies to:

Kerry Shannon Burke	Patrick J. Christmas
Matthew C. Franker	Chief Legal Officer
Covington & Burling LLP	REGENXBIO Inc.
One CityCenter	9804 Medical Center Drive
850 Tenth Street, N.W.	Rockville, Maryland 20850
Washington, D.C. 20001	(240) 552-8181
(202) 662-6000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.

Large accelerated filer		Accelerated filer	
Non-accelerated filer		Smaller reporting company	
		Emerging growth company	

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

EXPLANATORY NOTE

This Registration Statement on Form S-8 (the “Registration Statement”) is filed by REGENXBIO Inc. (the “Company”) for the purpose of registering additional shares of its common stock, par value $0.0001 per share (the “Common Stock”), under the Company’s 2015 Equity Incentive Plan (the “Incentive Plan”).

The number of shares of Common Stock available for issuance under the Incentive Plan is subject to an automatic annual increase as of the first business day of the Company’s fiscal year equal to the lower of (a) 4.0% of the total number of shares of Common Stock outstanding on December 31 of the prior year or (b) a number of shares of Common Stock determined by the Company’s Board of Directors (the “Incentive Plan Provision”). Accordingly, the number of shares of Common Stock available for issuance under the Incentive Plan was increased by 1,981,975 shares effective January 2, 2025. This Registration Statement registers the offer and sale of the 1,981,975 additional shares of Common Stock that are available for issuance under the Incentive Plan as a result of the Incentive Plan Provision.

Of the 17,928,064 shares of Common Stock currently authorized by the Incentive Plan, in addition to the shares, the offer and sale of which are being registered hereby, the Company has previously registered the offer and sale of: (a) 2,952,100 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on September 17, 2015 (Commission File No. 333-206984), (b) 1,052,538 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on March 3, 2016 (Commission File No. 333-209899), (c) 1,059,065 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on March 7, 2017 (Commission File No. 333-216508), (d) 1,251,810 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on March 6, 2018 (Commission File No. 333-223466), (e) 1,444,808 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on February 27, 2019 (Commission File No. 333-229910), (f) 1,479,696 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on February 26, 2020 (Commission File No. 333-236664), (g) 1,499,037 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on March 1, 2021 (Commission File No. 333-253725), (h) 1,713,246 shares of Common Stock to the Company’s Registration Statement on Form S-8 filed on March 1, 2022 (Commission File No. 333-263182), (i) 1,731,940 shares of Common Stock to the Company’s Registration Statement on Form S-8 filed on February 28, 2023 (Commission File No. 333-270116) and (j) 1,761,849 shares of Common Stock to the Company's Registration Statement on Form S-8 filed on February 27, 2024 (Commission File No. 333-277412) (collectively, the “Original Incentive Plan Registration Statements”).

Pursuant to General Instruction E to Form S-8 under the Securities Act of 1933, as amended, the contents of the Original Incentive Plan Registration Statements, including any amendments thereto or filings incorporated therein by reference are incorporated herein by reference and made part of this Registration Statement. Any items in the Original Incentive Plan Registration Statements not expressly changed hereby shall be as set forth in the Original Incentive Plan Registration Statements.

PART II

Information Required in the Registration Statement

Item 3. Incorporation of Documents by Reference.

The following documents (File No. 001-37553) previously filed with the Securities and Exchange Commission (the “SEC”) are hereby incorporated by reference:

•the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025 (the “2024 Annual Report”);

•the information specifically incorporated by reference into the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 from the Company’s definitive proxy statement on Schedule 14A for the 2024 Annual Meeting of Stockholders, filed with the SEC on April 4, 2024;

•all other reports filed with the SEC pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the Company’s 2024 Annual Report; and

•the description of the Company’s Common Stock contained inExhibit 4.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025, including any amendments or reports filed for the purposes of updating this description.

All reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities registered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents, except as to specific sections of such statements as set forth therein.

Unless expressly incorporated into this Registration Statement, a report furnished on Form 8-K (or any portion thereof so furnished) prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

Item 8. Exhibits.

Exhibit No.	Description
4.1*	Restated Certificate of Incorporation (incorporated by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on June 7, 2021).
4.2*	Amended and Restated Bylaws (incorporated by reference from Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed with the SEC on September 22, 2015).
4.3*	Specimen stock certificate evidencing the shares of Common Stock (incorporated by reference from Exhibit 4.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on August 17, 2015).
4.4*	2015 Equity Incentive Plan (incorporated by reference from Exhibit 10.3 to Amendment No. 2 to the Company’s Registration Statement on Form S-1, filed with the SEC on September 15, 2015).
4.5*	Form of Restricted Stock Unit Award Agreement for the 2015 Equity Incentive Plan (incorporated by reference from Exhibit 10.4 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021).
4.6*	Form of Stock Option Award Agreement for the 2015 Equity Incentive Plan (incorporated by reference from Exhibit 10.5 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021).
5.1	Opinion and Consent of Covington & Burling LLP.
23.1	Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.
23.2	Consent of Covington & Burling LLP (contained in Exhibit 5.1).
24.1	Power of Attorney (contained on signature page hereto).
107	Filing Fee Table.

* Incorporated by reference

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rockville, State of Maryland, on this 13th day of March, 2025.

REGENXBIO INC.
By:	/s/ Curran Simpson
	Curran Simpson
	President and Chief Executive Officer

POWER OF ATTORNEY AND SIGNATURES

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kenneth T. Mills and Patrick J. Christmas, and each of them, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Curran Simpson Curran Simpson	President, Chief Executive Officer and Director (Principal Executive Officer)	March 13, 2025
/s/ Mitchell Chan Mitchell Chan	Chief Financial Officer (Principal Financial and Accounting Officer)	March 13, 2025
/s/ Kenneth T. Mills Kenneth T. Mills	Chairman of the Board of Directors	March 13, 2025
/s/ Jean Bennett Jean Bennett	Director	March 13, 2025
/s/ Allan M. Fox	Director	March 13, 2025
Allan M. Fox
/s/ Alexandra Glucksmann Alexandra Glucksmann	Director	March 13, 2025
/s/ A.N. “Jerry” Karabelas A.N. “Jerry” Karabelas	Director	March 13, 2025
/s/ George Migausky George Migausky	Director	March 13, 2025
/s/ David C. Stump David C. Stump	Director	March 13 2025
/s/ Daniel Tassé Daniel Tassé	Director	March 13, 2025
/s/ Jennifer Zachary	Director	March 13, 2025
Jennifer Zachary

EX-5.1

EXHIBIT 5.1

March 13, 2025

REGENXBIO Inc.

9804 Medical Center Drive

Rockville, Maryland 20850

Ladies and Gentlemen:

We have acted as counsel to REGENXBIO Inc., a Delaware corporation (the “Company”), in connection with the registration by the Company under the Securities Act of 1933, as amended (the “Securities Act”), of the offer and sale of up to 1,981,975 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), under the Company’s 2015 Equity Incentive Plan (the “Plan”), pursuant to the Registration Statement on Form S-8 filed with the United States Securities and Exchange Commission on the date hereof (such registration statement is referred to herein as the “Registration Statement”).

We have reviewed such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or appropriate for the purposes of this opinion. We have assumed that all signatures are genuine, that all documents submitted to us as originals are authentic and that all copies of documents submitted to us conform to the originals.

We have relied as to certain matters on information obtained from public officials, officers of the Company and other sources believed by us to be responsible.

Based upon the foregoing, we are of the opinion that the Shares have been duly authorized and, when issued in accordance with the terms of the Plan and any individual agreements relating to such Shares, the Shares will be validly issued, fully paid and nonassessable.

We are members of the bar of the District of Columbia. We do not express any opinion herein on any laws other than the General Corporation Law of the State of Delaware.

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

Very truly yours,

/s/ Covington & Burling LLP

EX-23.1

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on FormS-8 of REGENXBIO Inc. of our report dated March 13, 2025relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in REGENXBIO Inc.'s Annual Report on Form 10-K for the year ended December 31, 2024.

/s/ PricewaterhouseCoopers LLP
Washington, District of Columbia
March 13, 2025

1

EX-FILING FEES

EXHIBIT 107

Calculation of Filing Fee Tables

Form S-8

(Form Type)

REGENXBIO Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

Security Type	Security Class Title	Fee Calculation Rule	Amount Registered(1)(2)	Proposed Maximum Offering Price Per Unit(3)	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
Equity	Common Stock, par value $0.0001 per share, to be issued under the Company’s 2015 Equity Incentive Plan	Other	1,981,975	$5.895(3)	$11,683,742.625 (3)	0.0001531	$1,788.781
Total Offering Amounts					$11,683,742.625		$1,788.781
Total Fee Offsets							$-
Net Fee Due							$1,788.781

(1)Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the registrant’s Common Stock that become issuable in respect of such securities by reason of any stock dividend, stock split, recapitalization or other similar transaction.

(2)Represents additional shares of the registrant’s Common Stock reserved for issuance under the registrant’s 2015 Equity Incentive Plan (the “2015 Plan”) pursuant to the provisions of the 2015 Plan that provide for an automatic annual increase in the number of such shares.

(3)Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act, and based upon the average of the high and low prices of the registrant’s Common Stock as reported on The Nasdaq Global Select Market on March 11, 2025.